SEARCH:   Advanced

Blood, 1 September 2005, Vol. 106, No. 5, pp. 1749-1754. Prepublished online as a Blood First Edition Paper on May 26, 2005; DOI 10.1182/blood-2005-03-1082. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-03-1082v1 106/5/1749    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Haining, W. N. Articles by Nadler, L. M. Search for Related Content PubMed PubMed Citation Articles by Haining, W. N. Articles by Nadler, L. M. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia W. Nicholas Haining, Donna S. Neuberg, Heather L. Keczkemethy, John W. Evans, Stephen Rivoli, Rebecca Gelman, Howard M. Rosenblatt, William T. Shearer, Javier Guenaga, Daniel C. Douek, Lewis B. Silverman, Stephen E. Sallan, Eva C. Guinan, and Lee M. Nadler From the Departments of Pediatric Oncology, Biostatistics and Computational Biology, and Medical Oncology, Dana-Farber Cancer Institute; Allergy/Immunology, Texas Children's Hospital; Vaccine Research Center, National Institutes of Health; Division of Hematology/Oncology, Children's Hospital, Boston; and Harvard Medical School. Despite profound T-cell immunodeficiency, most patients treated with chemotherapy do not succumb to infection. The basis for residual protective immunity in lymphopenic patients is not known. We prospectively measured T-cell numbers, thymopoiesis, and T-cell memory in 73 children undergoing a 2-year chemotherapy regimen for acute lymphoblastic leukemia (ALL) and compared them to an age-matched cohort of 805 healthy children. Most patients had profound defects in CD4 and CD8 T-cell numbers at diagnosis that did not recover during the 2 years of therapy. Thymic output and the fraction of naive T cells were significantly lower than in healthy controls. However, the remaining T-cell compartment was enriched for antigen-experienced, memory T cells defined both by phenotype and by function. This relative sparing of T-cell memory may, in part, account for the maintenance of protective immunity in lymphopenic patients treated for ALL. Moreover, because the memory T-cell compartment is least affected by ALL and its treatment, strategies to induce immunity to pathogens or tumor antigens in cancer patients may be most successful if they seek to expand pre-existing memory T cells. (Blood. 2005; 106:1749-1754) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. M. Coughlin, M. D. Fleming, R. G. Carroll, B. R. Pawel, M. D. Hogarty, X. Shan, B. A. Vance, J. N. Cohen, S. Jairaj, E. M. Lord, et al. Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma J. Clin. Oncol., December 20, 2006; 24(36): 5725 - 5734. [Abstract] [Full Text] [PDF] R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation Blood, February 15, 2006; 107(4): 1332 - 1341. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020